Rosacea Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight
Rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
(Albany, USA) DelveInsight's ' Rosacea Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of Rosacea, including historical and forecasted epidemiology, as well as Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The latest healthcare forecast report delivers a comprehensive analysis of Rosacea, offering critical insights into prevalence, revenue trends, and evolving Rosacea treatment options. The report discusses key statistics, including current and projected market sizes, while also delving into Rosacea symptoms and their impact on patients' quality of life.
It evaluates the progress and effectiveness of emerging therapies for Rosacea alongside an in-depth examination of the clinical trial landscape. This includes a detailed review of ongoing and upcoming studies that are set to shape the future of Rosacea treatment. With its rich data and forward-looking insights, this report serves as an indispensable resource for understanding market dynamics and advancements in the field of Rosacea.
Some of the key insights of Rosacea Market Report:
The rosacea market size is expected to experience significant growth during the forecast period (2024–2034). This growth is a direct consequence of various market-driving factors such as improving access to diagnosis and treatment, increased awareness and research, advancements in treatment options, and increasing prevalence of rosacea.
Emerging therapies for rosacea include AIV001, TP-04, B244, and others.
Key rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
In the US, the prevalence of rosacea is increasing, with around 16 million Americans affected, according to the American Academy of Dermatology.
In the UK, rosacea affects approximately 2 per 1,000 persons, with prevalence rates ranging from 0.10% to 22%.
In Germany, the prevalence of rosacea was around 12%, with erythematotelangiectatic (ETR) and papulopustular (PPR) subtypes accounting for 9% and 3%, respectively. About 18% of diagnosed cases were in individuals aged 18-30 years.
Rosacea is more common in females, with nearly 90% of cases in women compared to 15% in men. The most common subtypes were erythematotelangiectatic (60%), papulopustular (30%), phytates (20%), and ocular (40%).
The rosacea treatment market is currently led by EPSOLAY, a product by Sol-Gel Technologies and Galderma, which is expected to expand in the coming years.
On November 5, 2024, the FDA approved minocycline hydrochloride extended-release capsules (DFD-29, Emrosi) for treating inflammatory lesions caused by rosacea in adults. This approval followed positive Phase 3 trial results.
Rosacea Overview:
Rosacea is a chronic skin condition characterized by facial erythema (redness) that affects around 1 in 10 people worldwide. Rosacea symptoms vary widely, with some individuals experiencing persistent redness, visible blood vessels, and swollen, red bumps that resemble acne. The condition can be categorized into four types: erythematotelangiectatic rosacea, papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea. Many patients exhibit symptoms of more than one type, making diagnosis and treatment more complex.
Papulopustular rosacea, also known as inflammatory rosacea or type-2 rosacea, is commonly mistaken for acne due to the presence of 'whitehead' pustules and red, swollen bumps, particularly on the cheeks, chin, and forehead. This subtype of rosacea often flares up for weeks to months before subsiding temporarily. While the exact causes remain unclear, researchers suggest that genetic predisposition, immune responses to Bacillus oleronius and H. pylori infections, overproduction of cathelicidin protein, or Demodex mites living on the skin may play a role in its development.
The diagnosis of rosacea is largely based on patient history and physical examination. However, its symptoms can be confused with other skin conditions such as adult acne vulgaris, photodermatitis, seborrheic dermatitis, or contact dermatitis. This overlap of rosacea symptoms highlights the need for careful evaluation to ensure accurate diagnosis and treatment.
The therapeutic landscape of rosacea includes various drug classes used to treat rosacea, with treatments tailored based on the severity and subtype of the condition. The primary options include topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. For moderate cases of papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Maintenance therapy often involves topical agents like metronidazole. Among topical treatments, retinoids such as tretinoin, tazarotene, and adapalene are commonly prescribed to reduce erythema, papules, pustules, and telangiectasia.
Tretinoin, one of the most affordable and widely used topical retinoids, is often the drug of choice for treating rosacea symptoms. Topical antibiotics, including metronidazole, clindamycin, erythromycin, azelaic acid, benzoyl peroxide, and sulfacetamide, are also applied to the skin to combat surface bacteria and reduce inflammation. Among the new drugs for rosacea, EPSOLAY is the only US FDA-approved topical treatment for rosacea, highlighting the growing focus on targeted therapies to address unmet needs in this space.
With ongoing advancements, researchers continue to explore innovative drugs to treat rosacea, offering hope for improved management strategies and better quality of life for patients.
Rosacea Epidemiology:
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.
The Rosacea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total prevalent cases of rosacea
Diagnosed prevalent cases of rosacea
Type-specific diagnosed prevalent cases of rosacea
Treated cases of rosacea
Download the report to understand which factors are driving Rosacea epidemiology trends @ Rosacea Epidemiology Forecast
Rosacea Drugs Uptake and Pipeline Development Activities:
The drug uptake section examines the adoption rates of newly launched and upcoming Rosacea drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section offers a comprehensive look at the factors influencing the acceptance and success of Rosacea treatments in the market.
In addition, the therapeutics assessment section highlights the Rosacea drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a market share comparison among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption.
The report further explores the Rosacea pipeline, providing insights into therapeutic candidates at different stages of development. It identifies the key companies involved in creating targeted Rosacea treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Rosacea.
Rosacea Market Outlook:
The Rosacea market is poised for significant changes and growth in the coming years, driven by ongoing research and development efforts to address unmet medical needs. Current treatment options for rosacea, particularly for papulopustular rosacea, include approved and off-label therapies belonging to therapeutic categories, such as topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.
Topical antibiotics, the most commonly prescribed class of rosacea for all sexes and age groups, include metronidazole, clindamycin, erythromycin, and azelaic acid, with metronidazole leading in prescription volume. Oral TCAs like tetracycline, minocycline, and doxycycline (Oracea) are effective anti-inflammatory agents, with tetracycline being the most prescribed, followed by minocycline and doxycycline. While oral retinoids, such as isotretinoin, are often used as an off-label therapy, studies suggest that low-dose isotretinoin may offer better outcomes compared to doxycycline in some instances.
Despite the availability of these therapies, there remains a significant need for novel and more effective treatments to manage rosacea symptoms and improve patient outcomes. Encouragingly, many companies are developing innovative drugs to meet these unmet needs, which is expected to drive market growth. According to DelveInsight, the rosacea market in the 7MM (US, EU5, and Japan) is projected to experience substantial growth during the study period of 2020–2034, as advancements in research and therapeutic innovation continue to shape the market landscape.
To learn more about Rosacea therapies and Compsnies working in the treatment market, visit @ Rosacea Medication and Pipeline
Rosacea Market Drivers:
The increasing prevalence of rosacea, driven by factors like environmental changes and lifestyle, is pushing the demand for treatments.
Ongoing research and introducing new, more effective medications are encouraging growth in the rosacea market.
Rosacea Market Barriers:
The absence of a permanent cure for rosacea can lead to long-term patient frustration, affecting market confidence.
The stigma surrounding visible skin conditions may discourage people from seeking treatment, limiting market potential.
Scope of the Rosacea Market Report:
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Rosacea Companies: Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
Key Rosacea Therapies: AIV001, TP-04, B244, and others.
Rosacea Therapeutic Assessment: Rosacea currently marketed, and Rosacea emerging therapies
Rosacea Market Dynamics: Rosacea market drivers and Rosacea market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Rosacea Unmet Needs, KOL's views, Analyst's views, Rosacea Market Access and Reimbursement
To learn more about Rosacea companies working in the treatment market, visit @ Rosacea Clinical Trials and Therapeutic Assessment
Table of Contents:
1. Rosacea Market Report Introduction
2. Executive Summary for Rosacea
3. SWOT analysis of Rosacea
4. Rosacea Patient Share (%) Overview at a Glance
5. Rosacea Market Overview at a Glance
6. Rosacea Disease Background and Overview
7. Rosacea Epidemiology and Patient Population
8. Country-Specific Patient Population of Rosacea
9. Rosacea Current Treatment and Medical Practices
10. Rosacea Unmet Needs
11. Rosacea Emerging Therapies
12. Rosacea Market Outlook
13. Country-Wise Rosacea Market Analysis (2020–2034)
14. Rosacea Market Access and Reimbursement of Therapies
15. Rosacea Market Drivers
16. Rosacea Market Barriers
17. Rosacea Appendix
18. Rosacea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight:
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
23 minutes ago
- Winnipeg Free Press
Canadian auto sector hopeful a U.S. trade deal will come with carve-outs
Automotive industry leaders are hoping to see exemptions for vehicles compliant with the current trade deal as Canada and the U.S. continue discussions ahead of the upcoming tariff deadline. Friday marks the deadline in Canada's trade talks with the U.S., as President Donald Trump has threatened to impose 35 per cent tariffs on a wide variety of Canadian goods if the two countries don't reach an agreement before then. 'I think everybody has seen that the Americans, in spite of the fact that they are fighting us for no reason at all, have shown a tendency to show value for USMCA compliance,' said Flavio Volpe, president of the Automotive Parts Manufacturers' Association. He said roughly 50 per cent of the parts that go into vehicles made in Canada come from U.S. factories. 'I think there's some hope here that we can somehow work a deal that works for both sides, but includes a USMCA exemption on vehicles. If it does, then that would be a sign of relief, but it is also beneficial to Americans,' he said. The North American automobile industry is deeply integrated and vehicles imported into the United States that comply with the Canada-U.S.-Mexico Agreement on trade are still being hit with 25 per cent duties on their non-American components. Given the current trade agreement, which was negotiated by the first Trump administration, auto industry leaders are hoping to see carve-outs. David Adams, president and CEO of Global Automakers of Canada, said he ideally wants to see no tariffs on the industry. He highlighted that Canada previously negotiated a trade agreement with the U.S., and companies have since made significant investments based on that agreement. As the industry holds out hope for carve-outs, tariffs are taking their toll. General Motors reported last week that its profit declined 35 per cent in its second quarter as it took a US$1.1 billion hit from tariffs. In May, GM lowered its profit expectations for the year, bracing for an estimated tariff impact as high as US$5 billion in 2025. Meanwhile, Stellantis, the company behind brands including Jeep, Chrysler and Fiat, said in its latest earnings release that tariffs cost the company 300 million euros during the first half of the year. By and large, Volpe said companies have absorbed the impact of tariffs, which has resulted in lower sales volumes and higher costs. 'You can't run those losses indefinitely. You're going to have to make strategic decisions on what excess capacity you are going to fold inside the U.S., or you're going to concede those sales,' he said. Adams said that companies are 'making do,' but there are longer-term concerns. 'The challenge becomes how do you sustain the manufacturing base in Canada when, effectively, the manufacturing base here has been oriented around having duty-free exports of vehicles into the United States for the last 40-50 years,' he said. TD economist Marc Ercolao said in a note on Tuesday that Canada's automotive exports have fallen to late-2022 levels after tariffs took hold in April. 'Canadian automakers have since slashed production as they deal with trade challenges,' the report said. If the two countries are not able to reach a deal, Volpe said the current tariff regime would continue to hurt the industry. 'It's a slow bleed on the volume of vehicles made in Canada because they're, for the most part, destined for the U.S. So we would definitely be in emergency planning on how to make that vehicle manufacturing production more geared to Canadian consumers and Canadian consumption,' he said. However, he noted that Canada does not own the car companies, and the process would require billions of dollars in restructuring efforts and would be time-consuming. Despite the uncertainty surrounding the deal negotiations, Volpe said he thinks there's a chance a trade deal will be reached this week. 'I know for a fact that the right people are talking at an increased intensity around the clock,' he said. In contrast to previous trade discussions between Canada and the U.S., Volpe said these discussions have been 'very quiet.' He said sometimes, governments and negotiating teams use 'strategic leaks,' when required. However, this process has taken place behind closed doors, which Volpe said is likely the better way to negotiate with Trump at this time. On the Canadian side of the negotiations, Adams said that it appears Prime Minister Mark Carney is trying to temper expectations about the prospects of getting a deal, especially one without any tariffs. 'Maybe a good strategy because anything above that relatively low bar, in my view, could be viewed as success.' Canada-U.S. trade discussions are occurring after Trump recently announced a number of trade frameworks, notably with Japan and the European Union. Matt Blunt, president of the American Automotive Policy Council, posted on social media last week, saying 'any deal that charges a lower tariff for Japanese imports with virtually no U.S. content than the tariff imposed on North American-built vehicles with high U.S. content is a bad deal for U.S. industry and U.S. auto workers.' Volpe said he is hopeful there is an understanding that there is 'no comparing trading partners' and the Canadian and U.S. sectors are deeply integrated. 'The U.S. manufacturer of an assembly of vehicles doesn't rely on European factories or Japanese parts factories, or raw material supply. They don't buy Japanese steel and aluminum or European steel and aluminum,' he said. 'But all of that is true for Canada. Canadian capabilities are a force multiplier for the Americans. Also, our market is the number one export market for American-made vehicles.' — With files from Ian Bickis in Toronto and The Associated Press This report by The Canadian Press was first published July 31, 2025.
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
Trump's ill-advised trade war with Brazil
Opinion It's worth remembering that Brazil and the United States, long regional rivals, are deeply suspicious of the others' motives, are concerned about issues around dominance, control and independence and are locked in a tug-of-war to be recognized as the major power-broker in the wider region. The Brazilians, in particular, are open to cordial relations with Washington, but will not take their marching orders from the U.S. White House. The Americans, for their part, just want Brasilia to advance a policy agenda of supporting U.S.-friendly countries, following the U.S. lead, ensuring open markets and an attractive investment climate and fostering a stable order in the Americas. Recently, Trump did something ill-conceived, impulsive and counterproductive by imposing a stiff 50 per cent tariff (higher than any other country in this second tariff round) on all imports from Brazil — which is the largest economy in the region — on Aug. 1. In turn, Brazil's leftist president, Luiz Inácio Lula da Silva, promised to respond in kind against U.S. products entering the South American country. Eraldo Peres / The Associated Press Supporters of Brazil's former President Jair Bolsonaro stormed the Brazilian Supreme Court building, in Brasilia, in Brasilia, Brazil, in January, 2023. U.S. President Donald Trump is levying tariffs against Brazil to try to stop Bolsonaro's prosecution for attempting a coup to topple President Luiz Inacio Lula da Silva. Of course, there is nothing new about Trump imposing trade tariffs on other countries — as Canada can well attest. But what is new (and potentially very troubling) is that he appears to be doing so not on economic or commercial grounds. In fact, the U.S. actually registers a trade surplus with Brazil of some US$7.0 billion in 2024 — and roughly US$410 billion over the last 15 years. Some of America's largest businesses, such as Exxon Mobil, BlackRock and General Motors, have also found a welcoming corporate investment environment in Brazil. Instead, Trump has singled out Lula and Brazil's efforts to prosecute former far-right Brazilian president, and Trump's close friend and fellow traveller, Jair Bolsonaro for trying to discard the 2022 presidential electoral outcome. It is well known within Brazil that Bolsonaro had concocted plans to immediately call the election results fraudulent, to mobilize a supportive Brazilian military, to assassinate Lula (along with his vice president and a Supreme Court Justice) and to unconstitutionally cling to power through a coup d'état. Not surprisingly, Trump sees things much differently. He argues that Bolsonaro has been the victim of a political 'witch hunt' and much worse. In his July 9 letter to Lula, Trump noted angrily: 'The way that Brazil has treated former President Bolsonaro, a Highly Respected Leader throughout the World during his Term, including by the United States, is an international disgrace.' (There are also U.S. complaints against the Brazilian government for taking regulatory action against major American tech companies and social media platforms for disseminating misinformation and disinformation about Brazil's 2022 presidential election and its aftermath.) Bolsonaro, once dubbed the 'Trump of the Tropics,' was ideologically aligned with Trump and his MAGA base when he held political office from 2019-2022. Remember, there were people in Trump's inner circle in early 2023, such as Steve Bannon and Jason Miller, who wanted Bolsonaro to remain in South Florida and thus avoid facing prosecution for his alleged crimes. Since April of this year, though, the Brazilian National Congress passed the enabling legislation that would grant President da Silva the power to retaliate in kind against any U.S. trade levies. After Trump's recent tariff threat, he stated that 'any measure to increase tariffs will be addressed in accordance with the Brazilian Economic Reciprocity Law.' There is no disputing the fact that Brazil is deeply concerned about triggering a reduction of potentially 75 per cent of its exports to the U.S. (After all, the U.S. is Brazil's second largest trading partner after China.) But what Trump often fails to consider is the negative repercussions of his tariff tantrums. Tuesdays A weekly look at politics close to home and around the world. For instance, one-third of the coffee and half of the fresh orange juice that Americans consume at their breakfast table comes from Brazil. That means that Americans will automatically be paying more for those imported products and adding to their overall cost of living angst. I also can't imagine that Trump would want to anger his political base even more than he already has over the last few weeks. Secondly, Brazilians are very angry over what they believe is Trump's blatant interference in the country's domestic political affairs. As Lula pointed out: 'Brazil is a sovereign nation with independent institutions and will not accept any form of tutelage.' Accordingly, Trump's bumbling tariff move has only served to bolster Lula's standing in the polls. Then there's China. The Middle Kingdom has quickly become an important trade partner for Brazil. And Trump's latest move will only push Brasilia even closer to Beijing and thereby strengthen China's growing economic and political presence in the Americas. Clearly, countries that engage in trade wars invariably end up shooting themselves in the foot. Notwithstanding what Trump says, there are no winners in the types of clashes. The best thing for both sides would be for Trump and Lula to take a step back, allow cooler heads to prevail, and to recognize the mutual benefits of their important bilateral relationship. Peter McKenna is professor of political science at the University of Prince Edward Island in Charlottetown.
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
Building pharmaceutical sector strength
Manitoba's bioscience industry is inking collaboration commitments with other provinces as U.S. researchers increasingly look to move operations to Canada. Bioscience Association Manitoba signed a memorandum of understanding with BIOQuebec, its Quebec counterpart, in June. BAM is aiming for two more such agreements before Christmas. BROOK JONES / FREE PRESS Andrea Ladouceur, president of Bioscience Association Manitoba, at the group's Smart Park office on the University of Manitoba's Fort Garry campus. 'They are bigger provinces, they have more resources dedicated to the sector, they are more globally known,' said Andrea Ladouceur, BAM president. 'For Manitoba to be amongst those in a co-ordinated way, under an MOU, to help us collaborate — that's the fastest, most effective approach to bringing more opportunities to Manitoba.' Already, the pharmaceutical sector accounts for nearly seven per cent of Manitoba's GDP. Pfizer, Bausch Health and Dynacare have bases in the province. Ladouceur came into her role in January 2024; she's been seeking ways to grow interprovincial collaboration since. The election of U.S. President Donald Trump and resulting trade war tensions have helped bolster collaborative sentiment, she said. She's clocked a 'marked increase' in American companies enquiring about Manitoba. However, most queries are likely directed to larger provinces as U.S. research funds get slashed, she surmised. BIOQuebec confirmed it's fielded at least a dozen calls from Americans asking about relocating to the province since late spring. Life Sciences Ontario has discussed with a California-based business. The MOU with BIOQuebec — and, potentially soon, others — is meant to 'fill in the gaps in our ecosystem,' Ladouceur said. For example, if a Manitoba company needs a manufacturer for medicine it's creating, BAM might direct them to a BIOQuebec member. Quebec has also become 'the epicentre' of service providers able to find international manufacturers and ingredient makers that Canadian pharmaceutical companies need, Ladouceur said. She's hoping if U.S. companies land in Quebec, they'll be directed to Manitoba firms. BAM counts more than 200 members, including around 10 shared with BIOQuebec's pool of at least 300. Exposure to Manitoba might encourage Quebec companies to expand to the keystone province, Ladouceur said. 'This really is a limitless sector,' she added. 'There's more than enough for everybody.' BIOQuebec's interest in Manitoba stems from the province's 'dynamism,' said Benoît Larose, the organization's chief executive. 'In our experience, the smaller ecosystems are more willing to do business abroad,' he said. 'We don't have to convince them to do things with us — they want to do things with us.' BIOQuebec signed a memorandum of understanding with Life Sciences Ontario in March. Threats from the United States led to the MOUs, Larose said, noting BIOQuebec already had relationships with both associations. '(It) was a signal that we wanted to send to our own members,' he said. 'We should all be looking at the resources within Canada before considering doing business elsewhere. 'The 'elbows-up' attitude, that's what we decided to do.' Both Larose and Ladouceur noted U.S. tariffs and funding cuts have locked their members in uncertainty. Manitoba businesses import active pharmaceutical ingredients from the U.S. and export finished products south of the border. (Manitoba exported $211 million worth of packaged medicine in 2025's first quarter, a 70.5 per cent drop from the prior year. The Manitoba Bureau of Statistics pointed to a decline in U.S. imports.) Collaboration between provincial bioscience associations started growing pre-COVID-19 pandemic, said Jason Field, president of Life Sciences Ontario. The groups sit on the National Biotech Accord. Closeness emerged around 2017, when Ottawa sought to reform the patented medicine prices review board and drew industry pushback. It grew during the COVID-19 pandemic — while eyes were on pharmaceutical makers — and has continued during the Trump administration's latest reign, Field said. 'It's a real opportunity for Canada to differentiate itself on a global stage and be really competitive,' Field said. 'But … we have to make this an attractive business environment.' There's a gap in funding for bioscience companies who've reached the $2 million to $10 million range, and regulatory bodies tasked with approving Canadian health products have lacked speed, he asserted. Monday Mornings The latest local business news and a lookahead to the coming week. Inventions often start in Canada and end up commercialized by other countries, said Mary Argent-Katwala, senior director of stakeholder engagement for the Ontario Bioscience Innovation Organization. 'If a company left Vancouver, it's not that they're necessarily going to another province. They're probably going to Boston or San Diego,' Argent-Katwala said. OBIO is considering signing MOUs with peers in other provinces, Argent-Katwala added. Bioscience Association Manitoba aims to ink collaboration agreements across Canada. Such deals, including with BIOQuebec, could lead to more joint events and trade missions. Gabrielle PichéReporter Gabrielle Piché reports on business for the Free Press. She interned at the Free Press and worked for its sister outlet, Canstar Community News, before entering the business beat in 2021. Read more about Gabrielle. Every piece of reporting Gabrielle produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
